CERo Therapeutics (NASDAQ:CERO) Stock Rating Upgraded by D Boral Capital

D Boral Capital upgraded shares of CERo Therapeutics (NASDAQ:CERO) from a hold rating to a strong-buy rating in a research report released on Monday morning,Zacks.com reports.

Several other research analysts also recently weighed in on CERO. D. Boral Capital upgraded CERo Therapeutics from a “hold” rating to a “buy” rating and set a $30.00 price target for the company in a report on Monday. Maxim Group assumed coverage on CERo Therapeutics in a report on Monday, May 19th. They issued a “buy” rating and a $60.00 price target for the company.

CERo Therapeutics Stock Performance

Shares of CERo Therapeutics stock opened at $8.16 on Monday. CERo Therapeutics has a 1 year low of $6.71 and a 1 year high of $895.40. The business has a 50 day moving average price of $12.20 and a 200 day moving average price of $39.49.

CERo Therapeutics (NASDAQ:CERO) last issued its quarterly earnings data on Thursday, May 15th. The company reported ($31.80) earnings per share (EPS) for the quarter.

Institutional Trading of CERo Therapeutics

Several institutional investors have recently made changes to their positions in the stock. ARCH Venture Management LLC grew its stake in shares of CERo Therapeutics by 550.4% during the 4th quarter. ARCH Venture Management LLC now owns 9,393,561 shares of the company’s stock valued at $564,000 after buying an additional 7,949,265 shares during the period. Avantax Planning Partners Inc. grew its stake in shares of CERo Therapeutics by 89.9% during the 4th quarter. Avantax Planning Partners Inc. now owns 2,585,151 shares of the company’s stock valued at $155,000 after buying an additional 1,224,021 shares during the period. Armistice Capital LLC purchased a new stake in shares of CERo Therapeutics during the 1st quarter valued at $228,000. Finally, Parallel Advisors LLC purchased a new stake in shares of CERo Therapeutics during the 1st quarter valued at $161,000. 29.64% of the stock is owned by hedge funds and other institutional investors.

About CERo Therapeutics

CERo Therapeutics Holdings, Inc, an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.